Food Allergies: Biologics Bring Hope (AAN)

Price: FREE for members and non-members

Session recorded on May 10, 2023
Speaker: Lindsey Moore, DO, FACAAI, FAAP

Despite robust advancements in available treatment options for allergic diseases, options for food allergy treatment remain scarce. This discussion may help set the stage for a shared decision making approach in selecting various biologic medications for their patients. Topcis to be discussed include utilizing appropriate treatment strategies for patients with food allergy and how biologics treating atopic diseases may impact the treatment of food allergies.

Viewers can earn credit by completing the posttest questions.

This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Primary Care Providers
Pediatricians
Fellows-in-Training
Allied Health Professionals

Learning Objectives

Upon completion of this activity, learners should be able to:

1.    Review current management options for food allergy and identify limitations of this approach
2.    Discuss the therapeutic potential of biologics for food allergy

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
05/12/2023
Course expires: 
12/31/2024
Rating: 
0

All relevant financial relationships have been mitigated.

The individuals listed below disclose the following financial relationships:

Lindsey Moore, DO
Speaker
: Aimmune
Independent Contractor: Kenota
 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.